AGP Executive Report
Last update: 10 hours agoDrug Safety: The FDA will require all GLP-1 makers to warn of a rare risk of sudden vision loss linked to NAION; the absolute risk remains low. Stroke Prevention: The FDA approved Bayer’s daily pill asundexian, the first factor XIa inhibitor, to help prevent repeat strokes in some adults after stroke or TIA. Medical Manufacturing: India extended its medical-device production incentive scheme through 2035–36 and eased investment and sales requirements to encourage domestic production. Care Access: New AIIMS hospitals have logged more than six crore outpatient consultations since 2021–22, as 18 of 22 planned facilities are now fully functional. Physician Workforce: CMS distributed 200 Medicare-supported residency positions amid projections of a U.S. shortfall of up to 86,000 doctors by 2036. Diabetes Inequities: A study across 418 Southern counties linked higher diabetes rates with poverty, food insecurity and limited access to healthcare and places to exercise, underscoring the role of community conditions in prevention.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[When Patient Input Should Be Collected in the Clinical Research Process]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/30254235-956007081-0b6221fb0da7c0ffffd9ace6959bcbd4727e63ad-1280x720-200x113.jpeg)
